Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 4/20 | 0.49 |
| ▸ | MAOB | P27338 | 5/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5317430 | 0.90 | NOS1 (0.50) | LTA4HNOS1MAOBCHRNB2CHRNB4 | |
| SCHEMBL7248303 | 0.88 | NOS1 (0.51) | LTA4HNOS1MAOBCHRNB2CHRNB4 | |
| SCHEMBL17233207 | 0.86 | NOS1 (0.52) | LTA4HNOS1MAOBCHRNB2CHRNB4 | |
| SCHEMBL31706291 | 0.86 | NOS1 (0.52) | LTA4HNOS1MAOBCHRNB2CHRNB4 | |
| SCHEMBL6750419 | 0.86 | NOS1 (0.52) | LTA4HNOS1MAOBCHRNB2CHRNB4 | |
| SCHEMBL4104367 | 0.86 | NOS1 (0.52) | LTA4HNOS1MAOBCHRNB2CHRNB4 | |
| SCHEMBL7152797 | 0.83 | NOS1 (0.48) | LTA4HNOS1MAOBPPARA | |
| SCHEMBL7010616 | 0.83 | ALDH1A1 (0.44) | LTA4HNOS1ALDH1A1 | |
| SCHEMBL13725531 | 0.83 | MAOB (0.52) | LTA4HNOS1MAOBALDH1A1AOC3 | |
| SCHEMBL8140756 | 0.82 | NPC1 (0.47) | LTA4HALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233077-B1 | DOPAMINE D2 RECEPTOR LIGANDS | BROAD INST INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12428373-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20240400579-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4436976-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118510783-A | Spiro modulators of cholesterol biosynthesis and their use for promoting remyelination | 基因泰克公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2023097234-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097234-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20040116708-A1 | Insulin sensitizers; antidiabetic agents, antiinflammatory agents; inflammatory bowel disorders | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| EP-1375484-A1 | CARBOXYLIC ACIDS | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-20030212094-A1 | Novel cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1260512-A1 | NOVEL CYCLIC AMIDE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2002-11-27 | — | — | EP | disclosed |
| US-5147882-A | Cardiovascular disorders | KARL THOMAE GMBH (DE) | 1992-09-15 | — | — | US | disclosed |
| EP-0450429-A1 | Cyclophanes, process for their preparation and pharmaceuticals containing them | Dr. Karl Thomae GmbH (DE) | 1991-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | LTA4H 3452/4885NOS1 553/4885MAOB 2140/4885 |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | LTA4H 2479/4885NOS1 4427/4885MAOB 331/4885 |
| US-20240400579-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | MAG, NR1H2, PMP22 | LTA4H 2461/4885NOS1 2316/4885MAOB 2751/4885 |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | LTA4H 2676/4885NOS1 221/4885MAOB 2932/4885 |
| US-12428373-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | LTA4H 2479/4885NOS1 4427/4885MAOB 331/4885 |
| US-20030212094-A1 | Novel cyclic amide derivatives | SIGMAR1, OPRM1, OPRD1 | LTA4H 1436/4885NOS1 1302/4885MAOB 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.